Q3 Earnings Forecast for Organovo Issued By Zacks Small Cap

Organovo Holdings, Inc. (NASDAQ:ONVO) – Equities researchers at Zacks Small Cap increased their Q3 2025 earnings per share estimates for shares of Organovo in a research note issued to investors on Monday, November 11th. Zacks Small Cap analyst B. Sorensen now forecasts that the medical research company will post earnings per share of ($0.21) for the quarter, up from their prior estimate of ($0.25). The consensus estimate for Organovo’s current full-year earnings is ($0.77) per share. Zacks Small Cap also issued estimates for Organovo’s Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($0.77) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.75) EPS.

Separately, StockNews.com started coverage on shares of Organovo in a report on Monday. They set a “sell” rating on the stock.

Organovo Stock Performance

NASDAQ ONVO opened at $0.36 on Wednesday. The firm’s fifty day moving average price is $0.47 and its two-hundred day moving average price is $0.67. The stock has a market cap of $5.59 million, a PE ratio of -0.33 and a beta of 0.62. Organovo has a fifty-two week low of $0.35 and a fifty-two week high of $1.74.

Institutional Investors Weigh In On Organovo

An institutional investor recently bought a new position in Organovo stock. Armistice Capital LLC bought a new stake in Organovo Holdings, Inc. (NASDAQ:ONVO) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned approximately 6.46% of Organovo at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.23% of the company’s stock.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.